The through-line for personal injury litigation news this week is timing. Not liability, not causation theory, but the calendar: which bellwethers slipped, which mega-MDL finally closed its books, and which settlement funds are actually cutting checks versus still counting claims. For firms carrying inventory in these torts, the docket clock is the number that matters, because it drives intake posture, capital planning, and the lien work you should already be staging. Here is where the major dockets stood the week of August 6, 2026.
AFFF firefighting foam: the PI phase keeps lagging
The PFAS firefighting-foam litigation remains the clearest example of a two-speed docket. According to court filings, the personal-injury bellwether that had been set for October 2025 was vacated, and no replacement trial date has been entered. A new bellwether schedule is expected later in 2026, but as of this week the personal-injury track has no firm trial anchor.
That matters because the public-water side of AFFF has already moved. The earlier municipal water-provider settlements involving 3M and DuPont are a separate phase from the still-pending personal-injury claims, and they resolved on a very different timeline. The PI docket, meanwhile, now exceeds roughly 15,000 plaintiffs and continues to grow. Practitioners should read the vacated date as a reset, not a signal on the merits. The science workup on PFAS exposure and disease is dense, and the court is plainly sequencing the personal-injury phase behind the water-provider resolution rather than in parallel.
For anyone building an AFFF book, the practical takeaway is that causation development, occupational-exposure histories for firefighters, and diagnosis documentation should be locked down now. When the new schedule lands, the plaintiffs who are trial-ready will set the settlement tone. The ones still gathering records will not. It is also worth setting client expectations explicitly: the water-provider deals do not preview the personal-injury numbers, and treating a municipal settlement as a proxy for what an individual cancer plaintiff will recover invites disappointment down the line.
Covidien hernia mesh: a first bellwether finally has a date
The Covidien hernia mesh MDL, MDL-3029, has its first bellwether on the calendar. As reported, Patterson v. Covidien is set for July 13, 2026 in federal court in Boston. The case involves a Symbotex mesh alleged to have adhered to a plaintiff's organs and required revision surgery, which is the archetypal mesh-injury fact pattern: a device that was supposed to integrate cleanly instead created adhesions that forced a second operation.
Scale is worth keeping in perspective here. The Covidien docket is comparatively small, sitting at roughly 2,449 claims. The larger polypropylene mesh fight, the Bard and Davol litigation, holds well over 23,000 claims. So Patterson is not going to move the entire mesh universe, but it is the first real read on how a jury handles the Symbotex-specific coating and adhesion theory. Firms watching the broader product liability space should treat this bellwether as a data point on defect and warning arguments that may echo, but not control, in the Bard cases.
The defense playbook in mesh cases is well worn: attack the differential diagnosis, argue the revision was driven by surgical technique or patient-specific factors rather than the device, and press the learned-intermediary doctrine. The plaintiffs who survive that pressure are the ones with clean operative notes tying the revision to the specific mesh, not a general failure narrative.
3M Combat Arms earplugs: a mega-MDL reaches the end
The most instructive contrast this week is the 3M Combat Arms earplug litigation, MDL-2885, which is now fully dismissed and closed. Per the settlement administrator and the docket, all 391,283 cases have been resolved with zero pending. Roughly $3.04 billion of the $6.01 billion settlement has been issued, and the litigation has moved entirely into the payout phase.
It is genuinely rare to watch an MDL of that size go from active docket to closed. For firms, the earplug endgame is a live case study in the payout mechanics that follow a global resolution: claim scoring, evidentiary tiers, and the lag between an announced settlement and money actually landing in trust accounts. About half of the fund has been disbursed, which means a meaningful number of claimants are still waiting even after the litigation itself is over. That gap between resolution and payment is the part clients underestimate, and it is the part firms need to manage expectations around from the first intake call.
The earplug wind-down also carries a back-office lesson. When a docket of nearly 400,000 cases collapses into a pure payout operation, the firm work that remains is administrative rather than adversarial: verifying tier placement, reconciling the fee ledger, and clearing any residual liens before disbursement. Firms that built those workflows early moved their clients through the queue faster. Firms that treated the settlement as the finish line, rather than the start of a distribution project, are the ones now fielding calls about why the money has not arrived.
Camp Lejeune: offers climb, but the pipeline is enormous
Camp Lejeune remains the slowest-moving of the big-ticket dockets relative to its size. According to the latest figures, settlement offers now exceed $968 million and payouts exceed $801 million. Those numbers are real progress, but they sit against a pipeline of more than 400,000 administrative claims still working through the system. Congressional Budget Office exposure estimates have run as high as $21 billion, which frames just how early this process still is.
The court has set October 30, 2026 as a target for a global agreement, and that date is the one to watch. Two structural drags are worth flagging for anyone carrying Lejeune files. First, federal workforce reductions have slowed administrative processing, which pushes out the elective-option and litigation tracks alike. Second, the sheer claim volume means individual causation and exposure-duration proof still matters even inside a program that was designed to streamline recovery.
For intake, the practical posture is patience plus documentation. Residency and exposure-window proof, disease onset timing, and the Track selection decision all need to be handled deliberately. A rushed election can cost a client leverage they cannot recover.
J&J talc: a $5.5 billion deal, and this time no bankruptcy
The talc litigation produced the week's largest headline number. The $5.5 billion settlement announced in July 2026 is structured to resolve roughly 76,000 ovarian-cancer lawsuits, which the parties describe as about 99.75% of remaining state and federal claims. As of August 2026, about 68,914 cases remained pending in the MDL.
Two features distinguish this deal from what came before. It must be accepted by 95% of claimants to become final, so the threshold is high and the holdout math is real. And unlike the prior bankruptcy attempts, this settlement resolves only existing claims, not future ones. That is a significant departure. The earlier strategy tried to sweep future claimants into a channeling injunction through Chapter 11, and courts rejected it. This structure leaves the future-claims question open, which means the tort is being resolved for today's inventory but not permanently retired.
For firms, the 95% acceptance floor is the operational risk. If your clients are in the group being asked to accept, the allocation model and the release language deserve close reading before you advise anyone to sign.
What it means for practitioners
Across all five dockets, three themes should shape how firms operate this quarter.
- Intake posture: AFFF and Covidien mesh remain open books where trial-readiness will set settlement value, so front-load causation and records work. Camp Lejeune intake should be selective and documentation-heavy given the October target and the processing slowdown.
- Docket timing: Treat the vacated AFFF date and the July 2026 Patterson bellwether as your near-term signals, and the October 30 Lejeune target as the quarter's pivot point. The 3M earplug closure is a reminder that even after a global deal, payment timelines stretch.
- Liens, MSA, and set-asides: The earplug and talc dollars now flowing make lien resolution and Medicare set-aside analysis a present task, not a future one. Stage your lien and settlement workflow before checks issue, because the gap between a resolution and a disbursement is exactly when set-aside and subrogation disputes surface.
None of these dockets is standing still, even the ones without a trial date. We will keep tracking the schedule shifts and settlement mechanics as they land. For more mass-tort coverage, see our ongoing industry news reporting.